Kevin Wasserstein

Kevin Wasserstein was previously a Managing Director and represents Versant on the Autonomic Technologies, Cereve, Microfabrica, and ROX Medical Boards.

Before joining Versant in 2002, Kevin held a variety of marketing and business development roles at Guidant Corporation. Most recently he served as head of marketing in Guidant’s Cardiac Surgery Group, where he led the group’s product/market development and launch initiatives. In Guidant’s Peripheral and Carotid Group, Kevin developed and launched several first-generation stent and embolic protection devices while leading the carotid stent program’s marketing activities. Previously, in Guidant’s Compass Business Development Group, Kevin’s responsibilities included acquisition, licensing and investment with both private and public medical device companies, and corporate strategy. His operational experience also includes business development at Heartstream, and engineering design and engineering management at Hughes Aircraft Company.

Kevin holds both Bachelor’s and Master’s degrees in Mechanical Engineering, specializing in product design, as well as an MBA, all from Stanford University.

Current Versant Board Seats

Autonomic Technologies, Cereve, Microfabrica, ROX Medical

Previous Versant Board Involvement

Acclarent – observer (acquired), Cellutions, LipoSonix – observer (acquired), Lutonix (acquired), NDO Surgical (acquired), NeoGuide Systems – observer (acquired), Respicardia, St Francis Medical – observer (acquired), The Innovation Factory